Has Omolara Fakunle, MD received payments from drug or device companies?

Yes. Drug and device makers reported $13,318 in general payments to Omolara Fakunle, MD across 772 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Omolara Fakunle, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Omolara Fakunle, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Omolara Fakunle, MD

Endocrinology, Diabetes & Metabolism · Louisville, KYNPI 1780625129

Payments from drug & device makers

$13,318in general payments, 2019–2025

Across 772 payments — averaging $17.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$2K
Lilly USA, LLC$1K
Amgen$766
Insulet Corporation$723
Abbott$653
Amarin Pharma, Inc.$647
plus $7K from 48 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	134	$1,908
Lilly USA, LLC	64	$1,212
Amgen(2 entities)	42	$766
Insulet Corporation	48	$723
Abbott	31	$653
Amarin Pharma, Inc.	41	$647
Novartis	26	$598
Boehringer Ingelheim	32	$553
Tandem Diabetes Care, Inc.	21	$443
AstraZeneca(2 entities)	24	$384
Medtronic(2 entities)	20	$381
Esperion Therapeutics, Inc.	21	$322
AbbVie	17	$319
Sanofi-aventis U.S. LLC	18	$317
Corcept Therapeutics	16	$286
Bayer	18	$268
Dexcom, Inc.	19	$263
Amneal Pharmaceuticals LLC	12	$245
Recordati_rare_diseases_inc.	16	$244
Johnson & Johnson(2 entities)	18	$242
Xeris Pharmaceuticals, Inc.	12	$228
Ascendis Pharma Endocrinology Inc	6	$219
Pfizer	7	$174
Mannkind Corporation	11	$166
Antares Pharma, Inc.	10	$162
Ultragenyx Pharmaceutical Inc.	7	$127
Merck	8	$124
Neurocrine Biosciences, Inc.	5	$122
GRT US Holding, Inc.	4	$93
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	6	$90
Regeneron Healthcare Solutions, Inc.	5	$85
Companion Medical, Inc.	4	$76
EUSA Pharma (US) LLC	4	$68
Kyowa Kirin, Inc.	3	$64
BETA Bionics, Inc.	4	$58
BD	2	$56
Halozyme Inc	3	$54
Lifescan, Inc.	3	$54
Chiesi USA, Inc.	3	$54
Ascensia Diabetes Care US Inc.	3	$51
IBSA Pharma Inc.	4	$51
Madrigal Pharmaceuticals	2	$48
Cequr Corporation	1	$44
Shire North American Group Inc	3	$40
Sequel Med Tech, LLC	1	$37
Kowa Pharmaceuticals America, Inc.	3	$36
Amryt Pharma Holdings Ltd	2	$35
RGH Enterprises LLC	1	$33
Clarus Therapeutics Inc.	2	$27
Amphastar Pharmaceuticals, Inc.	1	$17
Eisai Inc.	1	$15
Takeda Pharmaceuticals U.S.A., Inc.	1	$12
Zealand Pharma US, Inc.	1	$12
Endo Pharmaceuticals Inc.	1	$12

How this compares

$13,318 in reported general payments places this provider in the 70th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.

See all endocrinology, diabetes & metabolism providers in Kentucky →

Medicare billing

Part B allowed, 2024

$114,289

Medicare patients

472

Services billed

9,201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Louisville

Harold BaysLouisville$12.9M
Hisham AlrefaiLouisville$720K
Sathya KrishnasamyLouisville$263K
Jahangir CyrusLouisville$155K
Mehdi PoorkayLouisville$81K
Sri Prakash MokshagundamLouisville$73K
Stephen WintersLouisville$21K
Angelino YsonLouisville$15K
Mary SelfLouisville$14K
Kaitlyn TuckerLouisville$9K

See the full list for Kentucky →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →